What Does End-of-Life Care Look Like for Scleroderma?

The short answer: End-of-life care for scleroderma (systemic sclerosis) addresses the complications of this rare autoimmune disease — pulmonary arterial hypertension, interstitial lung disease, renal crisis, and severe gastrointestinal involvement. The disease trajectory is highly variable, and most hospice teams have limited experience with it. Connecting with a specialist palliative care team familiar with scleroderma is important.

Understanding Scleroderma and Its End-Stage Complications

Scleroderma (systemic sclerosis) is a rare autoimmune disease characterized by abnormal collagen deposition causing fibrosis (scarring) of the skin and internal organs. Two major subtypes have different organ involvement patterns:

Diffuse cutaneous systemic sclerosis (dcSSc): Involves widespread skin thickening and early internal organ involvement — lungs, kidneys, heart, gastrointestinal tract.

Limited cutaneous systemic sclerosis (lcSSc, formerly CREST syndrome): More limited skin involvement; pulmonary arterial hypertension (PAH) is a major complication and cause of death.

The most common causes of death in scleroderma are pulmonary arterial hypertension, interstitial lung disease (pulmonary fibrosis), and historically, scleroderma renal crisis (now preventable with ACE inhibitors).

Pulmonary Arterial Hypertension in Scleroderma

PAH is a particularly feared and devastating complication. It causes progressive right heart failure — shortness of breath on exertion, then at rest, peripheral edema, and eventual right heart failure death. PAH-specific therapies (endothelin receptor antagonists, PDE5 inhibitors, prostacyclin analogues) can slow progression but not reverse it.

End-stage PAH is marked by severe resting dyspnea (breathlessness at rest), inability to perform basic activities, fluid overload, and progressive weakness. Comfort management — opioids for dyspnea, anxiolytics for air hunger anxiety, diuretics for fluid — is the focus of hospice care.

Interstitial Lung Disease in Scleroderma

Pulmonary fibrosis from scleroderma causes progressive loss of lung function over years. Antifibrotic medications (nintedanib) may slow progression, but the fibrosis is irreversible. End-stage ILD causes severe resting dyspnea similar to PAH. Supplemental oxygen, opioids, and anxiolytics manage breathlessness in hospice.

Gastrointestinal Complications

GI involvement in scleroderma can cause severe malabsorption, bacterial overgrowth, intestinal pseudo-obstruction, and inability to maintain nutrition by mouth. Nutritional management — specialized feeding regimens, IV nutrition (TPN) in some cases — requires expert guidance. In hospice, the focus shifts to comfort with whatever nutritional approach aligns with the patient's values.

Pain and Vasospasm

Raynaud's phenomenon (severe vasospastic attacks causing extreme pain in the fingers) and digital ulcers are painful and often resistant to treatment. Pain management in hospice includes medications for neuropathic pain, vasodilators where they help, and wound care for digital ulcers.

Finding Specialized Support

Because scleroderma is rare, most hospice teams will have limited experience with it. Connecting with a scleroderma specialist (rheumatologist, pulmonologist) who can advise the hospice team is important. The Scleroderma Foundation (scleroderma.org) has a national helpline and patient support network.

Frequently Asked Questions

What causes death in scleroderma?

The most common causes of death in scleroderma are pulmonary arterial hypertension (PAH) and interstitial lung disease (pulmonary fibrosis). Historically, scleroderma renal crisis was a leading cause, but it is now preventable with ACE inhibitor therapy. Cardiac complications and severe GI malnutrition also contribute.

When should a scleroderma patient consider hospice?

Hospice becomes appropriate for scleroderma when organ-directed therapies are no longer improving function and the focus shifts to comfort — typically when PAH or ILD has progressed to cause severe resting dyspnea, functional decline is significant, and the patient and family prioritize quality over quantity of life. Because scleroderma is rare, seek hospice programs with specialist palliative care support.

How is breathlessness managed in scleroderma hospice?

Opioids (low-dose morphine or hydromorphone) are the most effective medications for relieving the sensation of breathlessness, even when oxygen levels are adequate. Anxiolytics address the anxiety component of air hunger. Supplemental oxygen helps some patients. A fan directed at the face reduces the sensation of breathlessness in many patients through the trigeminal nerve cooling effect.

What is Raynaud's phenomenon in scleroderma?

Raynaud's phenomenon is exaggerated vasospastic attacks — dramatic color changes (white, then blue, then red) and severe pain in the fingers and toes triggered by cold or stress. In scleroderma, Raynaud's is often severe and can cause digital ulcers and tissue loss. In hospice, warmth, vasodilator medications, and pain management address Raynaud's symptoms.

What resources exist for scleroderma patients and families at end of life?

The Scleroderma Foundation (scleroderma.org) has a national helpline, local chapters, and patient support groups. Because of the disease's rarity, connecting with an academic medical center with scleroderma expertise — even just for consultation — can help local hospice teams provide better care. Online patient communities also provide peer support for patients and caregivers navigating end-stage scleroderma.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.